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Renal artery stenosis is frequently associated with resistant hypertension, which is
defined as failure to normalize blood pressure (BP) even when combined drugs are used.
Inhibition of PDE5 by sildenafil has been shown to increase endothelial function and
decrease blood pressure in experimental models. However, no available study evaluated
the baroreflex sensitivity nor autonomic balance in renovascular hypertensive rats treated
with sildenafil. In a translational medicine perspective, our hypothesis is that sildenafil
could improve autonomic imbalance and baroreflex sensitivity, contributing to lower blood
pressure. Renovascular hypertensive 2-kidney-1-clip (2K1C) and sham rats were treated
with sildenafil (45mg/Kg/day) during 7 days. At the end of treatment, BP and heart rate
(HR) were recorded in conscious rats after a 24-h-recovery period. Spontaneous and
drug-induced baroreflex sensitivity and autonomic tone were evaluated; in addition, lipid
peroxidation was measured in plasma samples. Treatment was efficient in increasing
both spontaneous and induced baroreflex sensitivity in treated hypertensive animals.
Inhibition of PDE5 was also capable of ameliorating autonomic imbalance in 2K1C
rats and decreasing systemic oxidative stress. Taken together, these beneficial effects
resulted in significant reductions in BP without affecting HR. We suggest that sildenafil
could be considered as a promising alternative to treat resistant hypertension.
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INTRODUCTION
Even though arterial hypertension is the most common modifiable risk factor for cardiovascular
diseases, it is still an important health problem worldwide. It is predicted that its prevalence
will reach 1/3 of global population by 2025 (Chokshi et al., 2013; Oparil and Schmieder, 2015).
Stenosis of renal artery is frequently associated with resistant hypertension. In those patients, the
usually available antihypertensive drugs protocol fail to normalize blood pressure (BP), even when
in association (Faselis et al., 2011; Carey, 2013; Vongpatanasin, 2014). Therefore, the urgency
in developing new approaches to treat arterial hypertension is clear. The experimental model
of renovascular hypertension proposed by Goldblatt mimics human renovascular hypertension
(Goldblatt et al., 1934; Navar et al., 1998). In that model, known as 2-kidney-1-clip (2K1C)
model, the unilateral renal artery stenosis reduces renal perfusion and chronically stimulates the
renin-angiotensin-aldosterone system (RAAS; Navar et al., 1998).
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Several studies describe that the central control of BP is
impaired during hypertension in humans and animal models,
possibly due to autonomic dysfunction (Irigoyen and Krieger,
1998; Campagnaro et al., 2012; Grassi et al., 2015). Angiotensin
II (Ang II) can directly affect central areas involved in autonomic
control. The activation of type 1 Ang II receptor (AT1R) and
the consequent production of reactive oxygen species (ROS) on
different brain nuclei involved in autonomic control are currently
well-acceptedmechanisms for explaining autonomic dysfunction
observed in arterial hypertension (Braga et al., 2011; de Queiroz
et al., 2013). In recent studies, our group and others have shown
that antioxidant therapy can reverse the reduced baroreflex
sensitivity in spontaneously hypertensive rats (SHR) and in
renovascular hypertensive rats (Nishi et al., 2010a; Botelho-Ono
et al., 2011; Guimarães et al., 2012; Monteiro et al., 2012).
Sildenafil is a specific inhibitor of phosphodiesterase 5
(PDE5), the enzyme responsible for degrading cyclic guanosine
monophosphate (cGMP). Thus, the main mechanism of action
for this drug is the increase in nitric oxide (NO)/cGMP signaling
pathway (Terrett et al., 1996; Palit and Eardley, 2010). In addition,
our group has recently shown that sildenafil exhibits antioxidant
properties (Balarini et al., 2013; Rodrigues et al., 2013; Dias et al.,
2014b; Fahning et al., 2015; Leal et al., 2015). However, the
efficacy of sildenafil in ameliorating central control of BP during
arterial hypertension has not been investigated. In the present
study, we aimed to evaluate the possible effects of sildenafil
treatment on the central control of blood pressure through
baroreflex sensitivity in 2K1C hypertensive rats. Furthermore, we
evaluated whether the treatment was able to improve autonomic
imbalance by reducing oxidative stress in those animals.
MATERIALS AND METHODS
Animals
Thirty eight Wistar rats (Rattus norvegicus) weighing 150–200 g
were used. Animals were bred and housed in a temperature and
humidity-controlled room set to a 12/12 h dark/light cycle with
access to water and regular chow (Labina R©, Purina, SP, Brazil) ad
libitum. Experimental procedures were performed in accordance
with National Institutes of Health (NIH) guidelines and protocols
were approved by Institutional Animal Care and Use Committee
(CEUA-UFPB protocol #042/2015).
Study Design
Animals were divided in four different groups: (1) Sham +
vehicle (n = 9): animals were submitted to sham surgery
and received vehicle during 7 days; (2) Sham + sildenafil
(n = 7): animals were submitted to sham surgery and received
sildenafil citrate during 7 days (45 mg/Kg/day) by gavage;
(3) 2K1C + vehicle (n = 11): animals were submitted to
renal artery clipping to induce renovascular hypertension and
received vehicle during 7 days; and (4) 2K1C + sildenafil
(n = 11): animals were submitted to renal artery clipping
to induce renovascular hypertension and received sildenafil
citrate during 7 days (45mg/Kg/day by gavage). Sildenafil dose
was chosen based on previous studies and on the difference
on pharmacokinetics for sildenafil in different species (Walker
et al., 1999; Ferreira-Melo et al., 2006; Guimarães et al., 2013).
Baseline blood pressure (BP) and heart rate (HR), baroreflex
function and autonomic tone evaluation test were performed
in most of the animals for each group, including the ones
used for typical raw tracings representation. Firstly, baseline BP
and HR were recorded for 40min. For drug-induced baroreflex
function studies, phenylephrine and sodium nitroprusside were
randomly administered with 15min interval between doses in
order to guarantee that cardiovascular parameters were back to
baseline values. Lastly, propranolol and atropine were randomly
administered with 3 h interval between doses. Details are given in
specific protocols ahead. Bodyweight and cardiovascular baseline
values for each experimental protocol is shown in Table 1 and
Table 2, respectively.
Renal Artery Clipping
The induction of renovascular hypertension was performed as
previously standardized in our laboratory (Botelho-Ono et al.,
2011; Queiroz et al., 2012). Briefly, animals were anesthetized
with a mixture of ketamine and xylazine (75 and 10mg/Kg,
respectively, i.p.). The surgical procedures were executed only
after the absence of withdraw and corneal reflexes. Right renal
artery was carefully exposed through a retroperitoneal incision.
A U-shaped silver clip (0.2mm wide opening) was positioned
around renal artery to decrease renal blood flow. Sham animals
underwent the same surgical process, except for the implantation
of the silver clip. After 5 weeks of surgery, the treatment protocol
with sildenafil or vehicle was started and continued for 7 days.
Hemodynamic Measures
Six weeks after the induction of hypertension (or sham
surgery), rats were anesthetized with a mixture of ketamine
and xylazine (75 and 10mg/Kg, respectively, i.p.) for catheters
implantation and direct hemodynamic measurements. The
surgical procedures were executed only after the absence of
withdraw and corneal reflexes. Polyethylene catheters were
inserted into the femoral artery and vein though a small inguinal
incision in order to allowing blood pressure (BP) recordings and
drug administration, respectively. Pulsatile arterial pressure was
recorded using a pressure transducer (BRPL2, WPI, Sarasota,
FL, USA) coupled to an amplifier and to an acquisition system
(PowerLab, ADInstruments, Bella Vista, NSW, Australia) using
a specific software (LabChart 5.0, ADInstruments, Bella Vista,
NSW, Australia). Systolic arterial pressure (SAP), mean arterial
pressure (MAP), diastolic arterial pressure (DAP), and heart rate
(HR) were derived from the pulsatile arterial pressure online.
Baroreflex Sensitivity Test
Baroreflex sensitivity was evaluated after a 24-h-recovery from
the catheter implantation surgery. After 40min of blood pressure
and heart rate baseline recordings, reflex responses were obtained
using vasoactive drugs as previously described using themodified
Oxford method (Botelho-Ono et al., 2011; Guimarães et al.,
2012; Alves et al., 2015). Briefly, a single bolus injection of
phenylephrine (PHE, 8µg/Kg) or sodium nitroprusside (SNP,
25µg/Kg) was randomly given in order to elicit changes in
blood pressure, which were similar in all groups. The second
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TABLE 1 | Weight values from the different groups.
Initial body
weight (g)
Final body
weight (g)
Right
kidney/Body
weight (mg/g)
Left
kidney/Body
weight (mg/g)
Heart
weight/Body
weight (mg/g)
Right kidney
weight (g)
Left kidney
weight (g)
Heart weight
(g)
Sham + Vehicle 173.8 ± 3.7 289.7 ± 13.8 4.4 ± 0.14 4.2 ± 0.17 3.7 ± 0.16 1.3 ± 0.04 1.2 ± 0.05 1.1 ± 0.07
Sham + Sildenafil 157.1 ± 1.2a 201.7 ± 12.6a 4.3 ± 0.20 4.3 ± 0.23 4.2 ± 0.28 0.85 ± 0.04d 0.9 ± 0.05a 0.83 ± 0.05d
2K1C + Vehicle 174.0 ± 2.8 272.8 ± 13.4 2.6 ± 0.37b,c 4.3 ± 0.31 4.1 ± 0.22 0.74 ± 0.12c 1.1 ± 0.05 1.1 ± 0.05
2K1C + Sildenafil 175.8 ± 4.2 283.3 ± 7.6 2.5 ± 0.4b,c 4.4 ± 0.31 3.6 ± 0.21 0.70 ± 0.13c 1.2 ± 0.08 1.0 ± 0.05
ap < 0.01 vs. all other groups.
bp < 0.01 vs. both sham groups.
cp < 0.05 vs. left side from the same group.
dp < 0.05 vs. sham + vehicle.
TABLE 2 | Values of MAP and HR before different drugs.
Before baroreflex test Before first autonomic blockade Before second autonomic blockade
MAP (mmHg) HR (bpm) MAP (mmHg) HR (bpm) MAP (mmHg) HR (bpm)
Sham + Vehicle 116 ± 3 390 ± 12 124 ± 4 355 ± 10 126 ± 2 347 ± 10
Sham + Sildenafil 121 ± 7 370 ± 21 120 ± 6 369 ± 15 116 ± 6 383 ± 22
2K1C + Vehicle 177 ± 6 381 ± 13 186 ± 10 390 ± 15 176 ± 14 402 ± 21
2K1C + Sildenafil 144 ± 3 367 ± 9 151 ± 8 329 ± 10 149 ± 6 328 ± 18
Values were compared by one-way ANOVA for the same group in the three different situations. No differences were found.
drug was administrated only after MAP and HR had returned
to baseline values (15min interval between drugs). Cardiac
baroreceptor reflex responses were evaluated at the maximum
(peak changes) responses (Giusti et al., 2011). Reflex changes
in HR were quantified and plotted as changes in heart rate
over changes in mean arterial pressure (1HR/1MAP, beats
per minute/mmHg). Data were analyzed by linear regression
using Prism 6 (GraphPad Software, Inc., San Diego, CA, USA)
and the slope of linear regression provided baroreflex gain for
each animal. Also, spontaneous baroreceptor reflex sensitivity
(SBRS) was evaluated as previously described (Braga et al., 2008;
Fazan et al., 2008) using the sequence method. A baroreflex
sequence was defined as a sequence of at least four heart beats in
which both systolic arterial pressure and pulse interval increased
(up sequences) or decreased (down sequences). The gain of
the baroreflex response was calculated and expressed as beats
per minute/mmHg). Tracings were analyzed using HemoLab
software (kindly provided by Dr. Harald Stauss, University of
Iowa, version 9.3). The absolute values for DAP and SAP over
which the spontaneous baroreflex was assessed were, respectively
(in mmHg): sham + vehicle: 111 ± 12 and 141 ± 4; sham +
sildenafil: 104 ± 7 and 143 ± 9; 2K1C + vehicle: 152 ± 6 and
209± 10; 2K1C+ sildenafil: 117.5± 4 and 177± 4.
Evaluation of Autonomic Control of Heart
Rate
Autonomic function was assessed in conscious animals (Botelho-
Ono et al., 2011; Xia et al., 2013). Autonomic blockade was
performed to evaluate the contribution of sympathetic and
parasympathetic nervous system to heart rate control. Changes in
heart rate after the injection of propranolol (β-blocker, 5mg/Kg,
i.v.) or atropine (muscarinic receptor blocker, 4mg/Kg, i.v.) were
calculated and expressed as 1HR. Variation in mean arterial
pressure (1MAP) was also measured. Each drug administration
was randomly chosen and separated from each other by an
interval of at least 3 h on the same day. The first autonomic
blockade was performed after MAP and HR had returned to
baseline values from baroreflex studies (15min). To assure
that there was no interference of baroreflex drugs or the first
autonomic blockage on autonomic responses, values for MAP
and HR prior to baroreflex, prior to the first autonomic drug
and prior to the second autonomic drug were provided in
Table 2. No differences were found among treatments within the
groups.
Oxidative Stress Assay
After the blood pressure recording experiments, blood was
collected through the venous catheter and centrifuged at
200 g, 4◦C, during 15min. Serum samples were collected
for thiobarbituric acid reactive species (TBARS) assay. The
concentration of malondialdehyde (MDA), an end product of
lipid peroxidation, was measured as an indicative of oxidative
stress. In this assay, MDA reacts with thiobarbituric acid to
produce a red-colored complex. Briefly, 400µL of perchloric
acid (7%) was added to 250µL serum, mixed and centrifuged
at 600 g, 4◦C, during 20min. The supernatant was collected,
added to 400µL of thiobarbituric acid (0.6%), heat at 60◦C
during 1 h and read at 532 nm. A standard curve of MDA
was constructed and the results were expressed as nmol of
MDA/mL.
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FIGURE 1 | Sildenafil reduces blood pressure in hypertensive rats. (A) Representative tracings from one animal of each group (Sham + vehicle, Sham +
sildenafil, 2K1C + vehicle, and 2K1C + sildenafil) showing pulsatile arterial pressure (PAP), mean arterial pressure (MAP), and heart rate (HR). (B) Effect of sildenafil
treatment during 7 days on MAP (a, p < 0.01 vs. sham + vehicle; b, p < 0.01 vs. sham + sildenafil; c, p < 0.05 vs. sham + vehicle; d, p < 0.01 vs. 2K1C + vehicle).
(C) Effect of sildenafil treatment during 7 days on HR.
Kidney and Heart Weight
After the experiments animals were euthanized with an overdose
of thiopental (200mg/Kg). Kidneys and heart were collected,
cleaned from connective tissue and weighed.
Statistical Analyzes
All results are expressed as mean± SEM. Statistical comparisons
among groups were performed by t-test or one-way ANOVA
followed by Tukey’s post hoc when appropriate. Statistical
analyzes were performed using Prism 6 and the differences were
considered significant when p < 0.05.
RESULTS
Body and Organs Weights
As shown in Table 1, animals from group sham + sildenafil
were smaller than others. Considering that, organ weights
were corrected by body weight. Clipped kidney from
both renovascular hypertensive groups showed atrophy, as
demonstrated by the reduction in right kidney weight/body
weight ratio in relation to the other kidney in the same group.
No differences were observed in left kidney weight/body weight
ratio nor heart weight/body weight ratio regarding the induction
of hypertension or treatment with sildenafil. Absolute values for
organ weights were also provided in Table 1.
Sildenafil Treatment Decreases Blood
Pressure in Hypertensive Rats
The results of mean arterial pressure (MAP) and heart rate (HR)
are summarized in Figure 1. Figure 1A shows representative
tracings of pulse arterial pressure (PAP), MAP, and HR from
one animal of each studied group. As expected, MAP was
increased in 2K1C + vehicle animals when compared with
sham + vehicle (175 ± 6 vs. 118 ± 3mmHg, p < 0.01;
Figure 1B). Sildenafil treatment reduced MAP when compared
to non-treated hypertensive animals (139± 5 vs. 175± 6mmHg,
p < 0.01; Figure 1B). The administration of sildenafil to sham
animals did not significantly modify MAP (121 ± 7 vs. 118
± 3mmHg). Conversely, HR was not different among all four
groups (Figures 1A,C).
Sildenafil Treatment Improves Baroreflex
Sensitivity in Hypertensive Rats
The representative tracings of changes in blood pressure and
heart rate after the administration of vasoactive drugs and
baroreflex gain are shown in Figures 2A,B. Vehicle-treated
hypertensive animals presented a reduction in baroreflex gain
when compared with sham + vehicle rats (−1.93 ± 0.12
vs. −3.63 ± 0.31 bpm/mmHg, p < 0.01; Figure 2B). The
treatment of hypertensive rats with sildenafil for 7 days was
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FIGURE 2 | Sildenafil restores baroreflex sensitivity in hypertensive rats. (A) representative tracings from one animal of each group (Sham + vehicle, Sham +
sildenafil, 2K1C + vehicle, and 2K1C + sildenafil) showing changes in pulsatile arterial pressure (PAP), mean arterial pressure (MAP), and heart rate (HR) in response to
sodium nitroprusside (25µg/Kg, open arrows) and phenylephrine (8µg/Kg, black arrows). (B) effect of sildenafil treatment during 7 days on pharmacologically-evoked
baroreflex sensitivity (baroreflex gain; a, p < 0.01 vs. sham + vehicle; b, p < 0.05 vs. sham + sildenafil; c, p < 0.01 vs. 2K1C + vehicle). (C) effect of sildenafil treatment
during 7 days on spontaneous baroreflex sensitivity (baroreflex gain; a, p < 0.01 vs. sham + vehicle; b, p < 0.05 vs. sham + sildenafil; c, p < 0.05 vs. 2K1C + vehicle).
FIGURE 3 | Effects of treatment with sildenafil on autonomic tonus to the heart. (A) Effect of atropine blockade on resting HR (a, p < 0.01 vs. sham + vehicle;
b, p < 0.05 vs. sham + sildenafil; c, p < 0.01 vs. 2K1C + vehicle). (B) Effect of propranolol blockade on resting HR (a, p < 0.01 vs. sham + vehicle; b, p < 0.01 vs.
sham + sildenafil; c, p < 0.01 vs. 2K1C + vehicle).
efficient in improving the baroreflex gain (−3.18 ± 0.23 vs.
−1.93 ± 0.12 bpm/mmHg, p < 0.01). These results were
similar in SBRS (Figure 2C). Hypertensive animals presented
reduced SBRS when compared with sham + vehicle animals
(−1.90 ± 0.22 vs. −3.95 ± 0.46 bpm/mmHg, p < 0.01) and
the treatment restored SBRS (−3.51 ± 0.29 bpm/mmHg vs.
2K1C + vehicle, p < 0.05). In both spontaneous and drug-
induced baroreflex activation, treatment of normotensive rats did
not modify baroreflex sensitivity (−3.65 ± 0.40 and −3.01 ±
0.33 bpm/mmHg, respectively, p > 0.05). Values for SBRS
and drug-induced baroreflex gain were not different within
groups.
Treatment with Sildenafil for 7 Days
Restores Autonomic Imbalance in
Hypertensive Rats
To test whether the treatment was efficient in correcting
autonomic imbalance in 2K1C animals, sympathetic, and
vagal tone to the heart were measured as the 1HR after
pharmacological blockade with propranolol and atropine
(Figure 3). Cardiac sympathetic drive was increased in 2K1C
+ vehicle group when compared with non-treated sham rats
(−60.9 ± 8 bpm vs. −23 ± 4 bpm, p < 0.01). Moreover, cardiac
vagal tone was reduced in hypertension (54.7 ± 8 vs. 115.8
± 10 bpm, p < 0.01). Treatment with sildenafil during 7
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days normalized sympathetic (−24.5 ± 3 bpm, p < 0.01) and
vagal tone (110 ± 9 bpm, p < 0.01) in 2K1C hypertension.
No differences were found in sham + sildenafil group when
compared to sham + vehicle. Changes in MAP after adrenergic
blockade with propranolol followed the same pattern as HR
(−34.6 ± 2mmHg in sham + vehicle vs. −60.4 ± 6mmHg in
2K1C + vehicle, p < 0.01 and −36.5 ± 3mmHg in 2K1C +
sildenafil, p < 0.01 vs. 2K1C + vehicle). No differences were
observed in sham + sildenafil. Regarding muscarinic blockade
with atropine, no differences were found in1MAP in all groups.
In addition, SBRS was evaluated before and after autonomic
blockade, as presented in Table 3. No differences were found in
SBRS after atropine or propranolol blockade within groups and
between different groups.
Sildenafil Treatment Reduces Oxidative
Stress in Hypertensive Rats
The quantification of MDA, a final product of lipid peroxidation,
is summarized in Figure 4. An increase in MDA concentration
of about 30% was observed in non-treated 2K1C animals when
compared with controls (1.67 ± 0.08 vs. 1.29 ± 0.06 nmol/mL,
p < 0.05). Sildenafil treatment given to 2K1C rats for 7 days
was able to reduce MDA levels when compared to non-treated
hypertensive rats (1.04 ± 0.07 vs. 1.67 ± 0.08 nmol/mL, p <
0.05). Treatment of sham animals with sildenafil did not modify
this parameter.
TABLE 3 | Values of spontaneous baroreflex gain before and after
autonomic blockade.
Before blockade After atropine After propranolol
Sham + Vehicle −3.95± 0.46 −3.52± 0.77 −3.73± 0.80
Sham + Sildenafil −3.65± 0.40 −3.67± 0.63 −4.64± 0.42
2K1C + Vehicle −1.90± 0.22a,b −2.41± 0.25 −2.73± 0.53
2K1C + Sildenafil −3.51± 0.29c −3.62± 0.77 −3.23± 0.35
Values were compared by one-way ANOVA for different groups under the same situation
and by t-test for the same group before and after blockade.
ap < 0.01 vs. sham + vehicle.
bp < 0.05 vs. sham + sildenafil.
cp < 0.05 vs. 2K1C + vehicle.
FIGURE 4 | Sildenafil effects on oxidative stress in hypertensive rats.
Quantification of malondialdehyde in serum of the different groups (a, p < 0.05
vs. sham + vehicle; b, p < 0.01 vs. sham + sildenafil; c, p < 0.01 vs. 2K1C +
vehicle).
DISCUSSION
In this study we aimed to investigate whether oral treatment
with a specific PDE5 inhibitor would improve baroreflex
sensitivity in renovascular hypertensive rats. This study is
part of a series of studies conducted by our research group,
which evaluate the effects of sildenafil administration in
animal models of cardiovascular diseases in a translational
medicine perspective. Our novel findings are that 7 days of
oral sildenafil administration to 2K1C rats were efficient in
improving baroreflex control of HR and reestablish autonomic
balance to levels of non-hypertensive animals. Furthermore,
the treatment decreased serum lipid peroxidation, which
is an indicative of oxidative stress. Taken together, these
favorable effects of sildenafil treatment were accompanied
by a significant reduction in BP in treated hypertensive
rats. We propose that sildenafil could be considered as a
potential alternative pharmacological approach to treat resistant
hypertensive patients.
The efficacy of sildenafil treatment in reducing mean arterial
pressure in 2K1C rats is remarkable (Figures 1A,B). This
observation is in accordance with previous results by us in
2K1C mice (Dias et al., 2014a,b; Fahning et al., 2015) and by
others in rats (Guimarães et al., 2013; Stegbauer et al., 2013).
In normotensive rats, sildenafil did not modify blood pressure,
which is in accordance with previously described (Ferreira-Melo
et al., 2006; Rossoni et al., 2007). In humans, treatment of
hypertensive patients with sildenafil during 15 days was able to
reduce blood pressure in a degree similar to commonly used
antihypertensive drugs, when given as monotherapy (Oliver
et al., 2006). It is important to highlight that the reduction in
BP elicited by sildenafil treatment was not accompanied by an
increase in heart rate (Figure 1C). This was also observed in
hypertensive patients that received sildenafil chronically (Oliver
et al., 2006).
Previous studies in hypertensive rats found a slight decrease
in total peripheral vascular resistance after chronic PDE5
inhibition, with no changes in HR. This suggested that the
blood pressure-lowering effect of this drug did not trigger a
reflex heart rate response (Ferreira-Melo et al., 2006). This
observation is crucial because one concern of sildenafil chronic
administration is the potential sympathetic activation, which
could limit or blunt BP-lowering effect (Taddei and Ghiadoni,
2006). Although it was described that intracerebroventricular
and intrathecal injection of sildenafil acutely increased blood
pressure and lumbar sympathetic activity in rats (Fazan et al.,
2008; Bombarda et al., 2011) and that, in humans, a single dose of
sildenafil increased sympathetically-mediated vascular tone and
norepinephrine plasma levels (Dopp et al., 2013), these results
are still controversial. Different clinical studies support the idea
that orally administrated sildenafil does not increase sympathetic
activity in humans (Taddei and Ghiadoni, 2006; Stirban et al.,
2009). In the present work we observed that the treatment did
not increase sympathetic drive to the heart (Figure 3B). On the
contrary, 2K1C+ sildenafil animals showed reduced sympathetic
drive to the heart when compared with non-treated hypertensive
animals.
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One important finding from the present work is that sildenafil
was efficient in restoring both spontaneous and drug-induced
baroreflex sensitivity (Figure 2), which was impaired in 2K1C
rats, as previously described (Botelho-Ono et al., 2011; Queiroz
et al., 2012). Although the adaptation of Oxford method using
single doses of SNP and PHE to elicit drug-induced baroreflex
sensitivity may not be the most adequate approach to address
baroreflex function, this method is well-accepted in the literature
(Braga et al., 2008; Botelho-Ono et al., 2011; Monteiro et al.,
2012; Alves et al., 2015). The main limitation of using single
bolus doses for vasoactive drugs to evaluate baroreflex function
is that it is not possible to build a complete sigmoid curve,
which would be more informative. In addition, spontaneous
baroreflex was evaluated during different baseline values for
each group. This might affect interpretation of the data since
each group may be on different parts of the baroreflex curve.
However, regardless of the point in the baroreflex curve, our
data regarding drug-induced baroreflex sensitivity is supported
by the spontaneous baroreflex data, both showing that sildenafil
improves baroreflex function in 2K1C rats. It is important to
highlight that differences in SBRS were not apparent between
groups after autonomic blockade. This can be explained by the
fact that, under autonomic blockade, the sequence technique
becomes less accurate in estimating baroreflex gain (Stauss et al.,
2006).
Nowadays, it is well-accepted that the mechanisms underlying
impaired baroreflex control of blood pressure in hypertension
involve, at least in part, Ang II-mediated increase in oxidative
stress along the axis formed by subfornical organ, paraventricular
nucleus of the hypothalamus and rostral ventrolateral medulla
(SFO-PVN-RVLM; Braga et al., 2011; de Queiroz et al.,
2013). Sildenafil was shown to interfere in renin-angiotensin-
aldosterone system (RAAS) during hypertension. Fourteen-days
treatment of 2K1C animals with sildenafil resulted in reduction
of Ang II in clipped kidney an increasing in Ang 1–7 in
kidney and plasma (Dias et al., 2014a,b). Ang 1–7 is a product
of the cleavage of Ang II by ACE2. It acts in a G-coupled
receptor (Mas receptor) and has opposite effects when compared
with Ang II (Santos et al., 2013). Although it was not directly
measured in the present work, we cannot rule out the possibility
that sildenafil treatment decreases RAAS signaling cascades
in brain regions involved in cardiovascular control such as
SFO-PVN-RVLM axis.
Interestingly, Aboutabl and colleagues showed that chronic
inhibition of PDE5 reduced blood pressure in NO-deficient rats
and increased plasma nitrite/nitrate and cGMP levels, suggesting
that sildenafil treatment could restore, at least in part, NO/cGMP
pathway in this model (Aboutabl et al., 2008). It is important
to highlight that oxidative stress and excessive production of
reactive oxygen species (ROS) are involved in the decreased
bioavailability of NO due to reaction with superoxide anions
to form peroxynitrite (Touyz, 2004). It is well-known that ROS
and NO play a crucial regulatory role in neurotransmission in
important brain areas of cardiovascular control (Kishi et al.,
2001; Kishi and Hirooka, 2012; Nishihara et al., 2012a,b). It
was previously shown by our group that, in addition to its
classic mechanism of action, sildenafil is also capable to increase
NO bioavailability in aorta and mesenteric arteriolar cells (Dias
et al., 2014a; Leal et al., 2015). If the same occurs in brain,
this could explain the amelioration in autonomic imbalance
promoted by sildenafil treatment in hypertensive rats (Figure 3).
Treated 2K1C animals showed decrease in sympathetic and
increase in parasympathetic tone to the heart. The lack of direct
measurement of sympathetic nerve activity is a limitation of the
study. Whether the amelioration of baroreflex is a cause or a
consequence of reduced blood pressure in treated animals is not
clear. Also, we cannot rule out the possibility that end organ
responses could be different across groups and contribute to
responses observed. However, in a translational perspective, the
main goal of any antihypertensive therapy is to reduce arterial
blood pressure, which was achieved by the treatment in the
present work.
In the present study we found that PDE5 inhibition decreased
serum lipid peroxidation, a marker of systemic oxidative stress.
Increase in serum MDA is associated with increased oxidative
stress in RVLM and PVN in 2K1C rats (Campos et al., 2011).
The observed antioxidant effect of sildenafil is in accordance with
previous investigations by us (Balarini et al., 2013; Rodrigues
et al., 2013; Dias et al., 2014b; Fahning et al., 2015) and by
others (Koupparis et al., 2005; Shukla et al., 2005; Schäfer et al.,
2008; Bivalacqua et al., 2009; Guimarães et al., 2013) in different
tissues. We believe that the amelioration of baroreflex sensitivity
is directly involved in reducing ROS, since different works from
our group (Nunes et al., 2010; Guimarães et al., 2012; Monteiro
et al., 2012; Queiroz et al., 2012; Alves et al., 2015) and others
(Nishi et al., 2010b, 2013) support the idea that antioxidant
treatment with natural or synthetic molecules can enhance
baroreflex gain in experimental hypertension. Oxidative stress
along SFO-PVN-RVLM pathway is involved in the decreased
baroreflex control of blood pressure during hypertension (Braga
et al., 2011). Considering that sildenafil can cross the blood-brain
barrier and act centrally (Raja and Nayak, 2004), our next step is
to investigate whether chronic inhibition of PDE5 with sildenafil
centrally decreases oxidative stress in key brain areas involved
in cardiovascular control and sympathetic tone. Although it was
demonstrated that PDE5 inhibition can decrease oxidative stress
due to reduction in the expression of important proteins in
the ROS-production cascades (Schäfer et al., 2008), information
about similar results in central nervous system is not available yet.
Our findings suggest that right renal artery clipping was
efficient in inducing renovascular hypertension (Figure 1). The
reduction in right kidney mass was confirmed by the reduction
in right kidney weight/body weight ratio in both 2K1C groups.
Sildenafil treatment did not modify this parameter (Table 1).
Although previous results from our group in 2K1C mice
demonstrated that PDE5 chronic inhibition was able to reduce
clipped kidney atrophy (Dias et al., 2014a,b), this difference is
probably due to the fact that the treatment started 14 days after
renal artery clipping, when renovascular hypertension is still
developing and is not yet fully established (Navar et al., 1998).
Although final body weight was different in sham + sildenafil
group, that does not seem to be an effect of the treatment, since
it was not observed in 2K1C + sildenafil group nor described in
the literature.
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In conclusion, this is the first study to show that inhibition
of PDE5 is capable to improve baroreflex sensitivity in
renovascular hypertensive rats. This improvement is associated
with correction of autonomic imbalance in 2K1C rats. It
was also documented that sildenafil treatment was efficient in
reducing systemic oxidative stress and reducing blood pressure
in treated animals. This study reinforces the concept that chronic
administration of PDE5 inhibitors could be useful in normalizing
blood pressure in resistant patients.
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